|
Platelet counts (× 109/L)
|
214.47 ± 64.55
|
125.81 ± 23.01
|
228.04 ± 57.76
|
< 0.001
|
|
Age (years)
|
61.77 ± 12.37
|
65.99 ± 11.06
|
61.13 ± 12.43
|
< 0.001
|
|
Male, n (%)
|
1158 (82.7%)
|
157 (84.4%)
|
1001 (82.4%)
|
0.498
|
|
Female, n (%)
|
243 (17.3%)
|
29 (15.6%)
|
214 (17.6%)
| |
|
SBP (mmHg)
|
122.00 ± 21.64
|
118.70 ± 21.82
|
122.50 ± 21.58
|
0.026
|
|
DBP (mmHg)
|
73.48 ± 12.76
|
71.63 ± 11.26
|
73.77 ± 12.96
|
0.034
|
|
Heart rate (bpm)
|
80.71 ± 16.54
|
80.78 ± 18.98
|
80.70 ± 16.14
|
0.954
|
|
Killip classification
|
1.42 ± 0.77
|
1.48 ± 0.88
|
1.41 ± 0.75
|
0.236
|
|
Hypertension, n (%)
|
724 (51.7%)
|
97 (52.2%)
|
627 (51.6%)
|
0.890
|
|
Diabetes, n (%)
|
367 (26.2%)
|
54 (29.0%)
|
313 (25.8%)
|
0.345
|
|
Hyperlipemia, n (%)
|
145 (10.3%)
|
14 (7.5%)
|
131 (10.8%)
|
0.175
|
|
Smoke, n (%)
|
622 (44.4%)
|
83 (44.6%)
|
549 (44.4%)
|
0.947
|
|
COPD, n (%)
|
34 (2.4%)
|
6 (3.2%)
|
28 (2.3%)
|
0.447
|
|
Prior MI, n (%)
|
72 (5.1%)
|
16 (8.6%)
|
56 (4.6%)
|
0.022
|
|
Prior stroke, n (%)
|
96 (6.9%)
|
19 (10.2%)
|
77 (6.3%)
|
0.051
|
|
Bleeding, n (%)
|
221 (15.8%)
|
46 (24.7%)
|
175 (14.4%)
|
< 0.001
|
|
Atrial fibrillation, n (%)
|
44 (3.1%)
|
76 (3.8%)
|
37 (3.0%)
|
0.601
|
|
CABG, n (%)
|
3 (0.2%)
|
0 (0.0%)
|
3 (0.2%)
|
0.498
|
|
Prior PCI, n (%)
|
140 (10.0%)
|
16 (8.6%)
|
124 (10.2%)
|
0.497
|
|
Laboratory characteristics
| | | | |
|
White blood cell (× 109/L)
|
11.82 ± 3.83
|
10.93 ± 3.52
|
11.95 ± 3.86
|
< 0.001
|
|
Serum creatinine (μmol/L)
|
103.78 ± 74.70
|
124.43 ± 104.83
|
100.61 ± 68.44
|
< 0.001
|
|
Triglycerides (mmol/L)
|
1.57 ± 1.20
|
1.35 ± 1.55
|
1.60 ± 1.14
|
0.010
|
|
Total cholesterol (mmol/L)
|
4.83 ± 1.19
|
4.33 ± 1.06
|
4.91 ± 1.19
|
< 0.001
|
|
LDL-C (mmol/L)
|
3.07 ± 1.01
|
2.65 ± 0.86
|
3.14 ± 1.02
|
< 0.001
|
|
HbA1c (%)
|
6.70 ± 1.73
|
6.85 ± 1.70
|
6.68 ± 1.74
|
0.271
|
|
Serum albumin (g/L)
|
33.26 ± 4.29
|
32.41 ± 4.11
|
33.39 ± 4.31
|
0.004
|
|
Hemoglobin (g/L)
|
136.24 ± 18.31
|
132.03 ± 19.59
|
136.88 ± 18.03
|
< 0.001
|
|
LVEF (%)
|
52.00 ± 11.71
|
50.79 ± 12.24
|
52.19 ± 11.61
|
0.130
|
|
Medication during hospital stay
| | | | |
|
Statins, n (%)
|
1384 (98.8%)
|
178 (95.7%)
|
1206 (99.3%)
|
< 0.001
|
|
Aspirin, n (%)
|
1370 (97.8%)
|
181 (97.3%)
|
1189 (97.9%)
|
0.636
|
|
Clopidogrel, n (%)
|
1384 (98.8%)
|
178 (95.7%)
|
1206 (99.3%)
|
0.593
|
|
CCB, n (%)
|
149 (10.6%)
|
27 (14.5%)
|
122 (10.0%)
|
0.065
|
|
Olmesartan, n (%)
|
225 (16.1%)
|
30 (16.1%)
|
195 (16.0%)
|
0.978
|
|
New antibiotic use, n (%)
|
240 (17.1%)
|
53 (28.5%)
|
187 (15.4%)
|
< 0.001
|
|
Procedural characteristics
| | | | |
|
Radial access, n (%)
|
1191 (85.0%)
|
155 (83.3%)
|
1036 (85.3%)
|
0.491
|
|
Femoral assess, n (%)
|
210 (15.0%)
|
31 (16.7%)
|
179 (14.7%)
| |
|
Contrast volume, (mL)
|
114.01 ± 42.81
|
117.86 ± 42.40
|
113.41 ± 42.86
|
0.213
|
|
Number of stents, (n)
|
1.30 ± 0.82
|
1.38 ± 0.88
|
1.28 ± 0.81
|
0.153
|
|
Total length of stent, (mm)
|
32.51 ± 22.38
|
34.67 ± 23.04
|
32.28 ± 22.27
|
0.158
|
